🏭 This agreement ensures U.S. manufacturing of Regeneron’s biologic medicines.
📈 Expansion plans at FUJIFILM’s facility in North Carolina will boost production capacities.
🤝 Both companies are committed to meeting high standards and creating new jobs.
🌍 FUJIFILM aims to contribute to the growing biopharmaceutical market.
Introduction:
FUJIFILM Diosynth Biotechnologies has entered into a significant long-term manufacturing agreement with Regeneron Pharmaceuticals, marking a substantial investment in biopharmaceutical production in the United States.
- FUJIFILM Diosynth Biotechnologies signed a 10-year, $3 billion manufacturing supply agreement with Regeneron Pharmaceuticals for U.S.-based production of biologic medicines.
- The agreement will leverage FUJIFILM’s new biopharmaceutical manufacturing facility in Holly Springs, North Carolina, which is set to commence operations later this year.
- Future capacity expansions are planned in both Europe and the United States, with a $7 billion investment underway to enhance manufacturing capabilities.
- The collaboration aims to implement the “kojoX™” modular manufacturing network, ensuring supply chain security and efficient technology transfers across global sites.
- FUJIFILM aims to create 1,400 new jobs in North Carolina by 2031, with 500 positions already added as part of this expansion effort.
Conclusion:
This partnership underscores the growing importance of biopharmaceutical manufacturing in the U.S. and highlights FUJIFILM’s commitment to investing in local production capabilities and workforce development. The anticipated expansions and innovative manufacturing network are positioned to support future growth in biopharmaceutical development and supply.
